Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DW0Z1Y
|
|||
| Drug Name |
IU1
|
|||
| Synonyms |
314245-33-5; 1-[1-(4-Fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(1-pyrrolidinyl)ethanone; 1-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(pyrrolidin-1-yl)ethan-1-one; IU-1; 1-[1-(4-fluorophenyl)-2,5-dimethylpyrrol-3-yl]-2-pyrrolidin-1-ylethanone; 1-(1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)-2-(pyrrolidin-1-yl)ethanone; CHEMBL1410015; MFCD01917473; 1-(1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)-2-(pyrrolidin-1-yl)ethan-1-one; 1-[1-(4-Fluoro-phenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-pyrrolidin-1-yl-ethanone; Usp14 inhibitor; MLS001032847; GTPL8880; SCHEMBL6923146; ZINC38235; DTXSID80350196; HMS1726C11; HMS2742M13; HMS3653I09; HMS3743A07; AMY24153; BCP12722; EX-A2079; 2486AH; BDBM50437694; s7134; AKOS000811299; IU1, >=98% (HPLC); CCG-190730; CS-7546; MCULE-9620933012; NE48827; QC-8208; SB19054; NCGC00249377-01; NCGC00249377-04; NCGC00249377-08; AC-32694; DA-33458; HY-13817; SMR000363441; ST054127; AB0097167; FT-0716455; MLS001032847-02; SW219677-1; EN300-72884; SR-01000010584; J-018415; SR-01000010584-1; Z55133506; F1142-1244; 1-[1-(4-fluorophenyl)-2,5-dimethylpyrrol-3-yl]-2-pyrrolidinylethan-1-one; 1-[1-(4-FLUOROPHENYL)-2,5-DIMETHYLPYRROL-3-YL]-2-(PYRROLIDIN-1-YL)ETHANONE
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Neurodegenerative disorder [ICD-11: 8A20-8A23] | Preclinical | [1] | |
| Company |
Proteostasis Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H21FN2O
|
|||
| Canonical SMILES |
CC1=CC(=C(N1C2=CC=C(C=C2)F)C)C(=O)CN3CCCC3
|
|||
| InChI |
1S/C18H21FN2O/c1-13-11-17(18(22)12-20-9-3-4-10-20)14(2)21(13)16-7-5-15(19)6-8-16/h5-8,11H,3-4,9-10,12H2,1-2H3
|
|||
| InChIKey |
JUWDSDKJBMFLHE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 314245-33-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ubiquitin carboxyl-terminal hydrolase 14 (USP14) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov. 2018 Jan;17(1):57-78. | |||
| REF 2 | Neurotoxic mechanisms by which the USP14 inhibitor IU1 depletes ubiquitinated proteins and Tau in rat cerebral cortical neurons: Relevance to Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1157-1170. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.